Tired of watching your portfolio crawl along? Standard investment advice often includes diversifying into bland, safe bets. But what if you desire higher returns, even if it means more risk? Strategic investment in well-researched, riskier wild-card stocks can be the secret ingredient to amplifying your gains. Yes, there’s a chance of getting burned, but with careful selection and a dash of courage, you could just as easily win. So, ditch the boring and consider embracing the bold. Not all investors have th ...

NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between December 1, 2023 and April 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-sub ...

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as me ...

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as m ...

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=88044&from=3 CLASS PERIOD: December 1, 2023 t ...

While their share prices have traveled different paths recently, the similarity between the two companies is striking.Altimmune (ALT 4.15%) and Viking Therapeutics (VKTX 4.41%) have a lot of features in common, but, at least for the moment, the performance of their stocks is not one of them. Whereas Viking's shares are up by 610% over the last three years, Altimmune's are down by 54%.However, there's more than one argument for why Altimmune's next act could look a lot more like Viking's trajectory. So let's ...

NEW YORK, June 29, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 5, 2024.To join the Altimmune class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq. toll ...

文章核心观点 - 阿尔泰默恩(Altimmune)正在研发一种新的减肥药物pemvidutide,该药物在临床试验中显示出较好的减肥效果,且主要减掉脂肪而非肌肉,这可能成为目前市场上主导的减肥药物Wegovy的潜在竞争对手 [1][4][5][7] - 阿尔泰默恩目前现金充足,研发支出较低,在获得监管批准前有较长的运营周期 [8][9] - 尽管存在一定风险,但阿尔泰默恩的减肥药物候选药物有望在未来成为一个更有利于某些人群(如老年人)的选择 [13][14] 公司概况 - 阿尔泰默恩是一家小型生物科技公司,目前有两个处于II期临床试验阶段的项目,都在研究同一种分子pemvidutide [3] - 其中针对肥胖症的项目是对抗Wegovy的潜在竞争对手 [4] - 公司目前现金储备充足,研发支出较低,在获得监管批准前有较长的运营周期 [8][9] 行业概况 - 减肥药物市场竞争激烈,由诺和诺德(Novo Nordisk)的Wegovy和Ozempic等药物主导 [1][14] - 阿尔泰默恩的新药如果获批上市,将需要与诺和诺德、礼来(Eli Lilly)等大型制药公司展开竞争 [14]

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), of the important July 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK, June 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=87822&from=4CLASS PERIOD: December 1, 2023 to April ...